Call for Paper for Special Issue

(Drug-Eluting Stents and Bioresorbable Scaffolds) 

Submission for Special Issue

Deadline : December 31,  2024


1.  Comprehensive manuscript entitled: "Drug-Eluting Stents and Bioresorbable Scaffolds – Current State of Knowledge on Microparticles-Coated, Controlled-Release Drug-Eluting Stents:  from Pharmacology to Efficacy and Safety."

2.  Special Issue entitled "Drug Eluting Stents for Cardiovascular Disease" from Preclinical to Clinical Applications to Coronary Artery Occlusions, In-Stent Complications, Pharmacology, Safety and Effectiveness.


All types of articles including Review Articles, Original Articles, Editorials and Case Report will be accepeted.

Lead Guest Editor:



M. Reza Sadaie (Ph.D.)

Consultant, Senior Scientist,
Research & Development, NovoMed Consulting, Germantown, MD 20874, USA

Scopus ID: 6701507149





Guest Editors:


Soodabeh Davaran (Ph.D.)

Professor of Medicinal Chemistry,
Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Yeditepe University, Istanbul, Turkey

Member of the club of UNESCO medal "Contribution to development of nanoscience and nanotechnology”

Scopus ID: 6603349891

Google Scholar



Hamed HamishehKar (Ph.D) 

Professor in the Pharmaceutical Sciences, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Scopus ID: 55179207800

Google Scholar





Leila Roshangar (Ph.D.)

Professor of Histology & Embryology, tissue engineering(skin),integrative regeneratve medicine. Tabriz Universiry of medical sciences,IRAN.

Scopus ID: 23019793700

Google Scholar



Submit Your paper


Platinum* Open Access

*This Platinum Open Access journal publishes articles totally free of charge for the authors and provides unrestricted access to the published content through its website. 





Indexing & Abstracting:




Supported by:


Society of Urological Research and Education (SURE)


Medical Council of the Islamic Republic of Iran, Division of Tabriz



Iranian Scientific Society of Intensive Care 


Follow Us on: